Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.56
ACRX's Cash to Debt is ranked higher than
71% of the 518 Companies
in the Global Medical Devices industry.

( Industry Median: 2.03 vs. ACRX: 2.56 )
ACRX' s 10-Year Cash to Debt Range
Min: 0.31   Max: N/A
Current: 2.56

Equity to Asset 0.54
ACRX's Equity to Asset is ranked higher than
62% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. ACRX: 0.54 )
ACRX' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.69
Current: 0.54

-0.01
0.69
F-Score: 2
Z-Score: -1.54
M-Score: -4.67
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -763.87
ACRX's Operating margin (%) is ranked lower than
55% of the 492 Companies
in the Global Medical Devices industry.

( Industry Median: 5.14 vs. ACRX: -763.87 )
ACRX' s 10-Year Operating margin (%) Range
Min: -1805.22   Max: -22.6
Current: -763.87

-1805.22
-22.6
Net-margin (%) -636.39
ACRX's Net-margin (%) is ranked lower than
54% of the 492 Companies
in the Global Medical Devices industry.

( Industry Median: 3.47 vs. ACRX: -636.39 )
ACRX' s 10-Year Net-margin (%) Range
Min: -1875.09   Max: -79.4
Current: -636.39

-1875.09
-79.4
ROE (%) -63.10
ACRX's ROE (%) is ranked higher than
51% of the 486 Companies
in the Global Medical Devices industry.

( Industry Median: 4.76 vs. ACRX: -63.10 )
ACRX' s 10-Year ROE (%) Range
Min: -130.03   Max: -43.78
Current: -63.1

-130.03
-43.78
ROA (%) -36.74
ACRX's ROA (%) is ranked higher than
55% of the 520 Companies
in the Global Medical Devices industry.

( Industry Median: 1.86 vs. ACRX: -36.74 )
ACRX' s 10-Year ROA (%) Range
Min: -134.55   Max: -26.84
Current: -36.74

-134.55
-26.84
ROC (Joel Greenblatt) (%) -480.97
ACRX's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 7.57 vs. ACRX: -480.97 )
ACRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2973.59   Max: -173.98
Current: -480.97

-2973.59
-173.98
Revenue Growth (3Y)(%) 26.00
ACRX's Revenue Growth (3Y)(%) is ranked higher than
97% of the 350 Companies
in the Global Medical Devices industry.

( Industry Median: 4.60 vs. ACRX: 26.00 )
ACRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 26
Current: 26

0
26
EBITDA Growth (3Y)(%) -15.00
ACRX's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. ACRX: -15.00 )
ACRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -15
Current: -15

EPS Growth (3Y)(%) -12.80
ACRX's EPS Growth (3Y)(%) is ranked higher than
69% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. ACRX: -12.80 )
ACRX' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -12.8
Current: -12.8

» ACRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ACRX Guru Trades in Q2 2014

Louis Moore Bacon 50,000 sh (+38.89%)
» More
Q3 2014

ACRX Guru Trades in Q3 2014

Paul Tudor Jones 11,400 sh (New)
Louis Moore Bacon Sold Out
» More
Q4 2014

ACRX Guru Trades in Q4 2014

Paul Tudor Jones Sold Out
» More
Q1 2015

ACRX Guru Trades in Q1 2015

Paul Tudor Jones 52,600 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with ACRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.80
ACRX's P/B is ranked higher than
71% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 3.92 vs. ACRX: 3.80 )
ACRX' s 10-Year P/B Range
Min: 2.16   Max: 78
Current: 3.8

2.16
78
P/S 29.20
ACRX's P/S is ranked lower than
61% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 4.21 vs. ACRX: 29.20 )
ACRX' s 10-Year P/S Range
Min: 7.21   Max: 163
Current: 29.2

7.21
163
Current Ratio 4.26
ACRX's Current Ratio is ranked higher than
81% of the 514 Companies
in the Global Medical Devices industry.

( Industry Median: 2.67 vs. ACRX: 4.26 )
ACRX' s 10-Year Current Ratio Range
Min: 0.43   Max: 20.39
Current: 4.26

0.43
20.39
Quick Ratio 4.26
ACRX's Quick Ratio is ranked higher than
85% of the 514 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. ACRX: 4.26 )
ACRX' s 10-Year Quick Ratio Range
Min: 0.43   Max: 20.39
Current: 4.26

0.43
20.39

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.10
ACRX's Price/Net Cash is ranked higher than
98% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ACRX: 5.10 )
ACRX' s 10-Year Price/Net Cash Range
Min: 2.2   Max: 25
Current: 5.1

2.2
25
Price/Net Current Asset Value 5.10
ACRX's Price/Net Current Asset Value is ranked higher than
95% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ACRX: 5.10 )
ACRX' s 10-Year Price/Net Current Asset Value Range
Min: 2.14   Max: 927
Current: 5.1

2.14
927
Price/Tangible Book 3.70
ACRX's Price/Tangible Book is ranked higher than
84% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. ACRX: 3.70 )
ACRX' s 10-Year Price/Tangible Book Range
Min: 2.08   Max: 57.94
Current: 3.7

2.08
57.94
Price/Median PS Value 0.70
ACRX's Price/Median PS Value is ranked higher than
96% of the 580 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. ACRX: 0.70 )
ACRX' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 3.61
Current: 0.7

0.17
3.61
Earnings Yield (Greenblatt) -36.60
ACRX's Earnings Yield (Greenblatt) is ranked lower than
59% of the 505 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ACRX: -36.60 )
ACRX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -46.1   Max: 0
Current: -36.6

-46.1
0

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:R5X.Germany,
AcelRx Pharmaceuticals Inc was was incorporated in Delaware on July 13, 2005 as SuRx, Inc. In January 2006, the Company has changed its name to AcelRx Pharmaceuticals, Inc. It is a development stage company. The Company is a specialty pharmaceutical company engaged in the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company's main product candidate, Zalviso, formerly known as the Sufentanil NanoTab PCA System, or ARX-01, is currently under review by the FDA for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. In addition, in December 2013, the Company entered into a collaboration agreement with Grünenthal for the commercialization of Zalviso in Europe and Australia. Its sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Its registered trademarks include ACELRX and NANOTAB.
» More Articles for ACRX

Headlines

Articles On GuruFocus.com
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against AcelRx Pharmaceutica Oct 15 2014 
Weekly CFO Buys Highlight: BK, MWW, BLD, ACRX, PSEC Sep 12 2011 

More From Other Websites
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June May 22 2015
AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June May 22 2015
7 Biotech Stocks Moving Off The UBS Healthcare Conference May 19 2015
AcelRx Pharmaceuticals (ACRX) Looks Good: Stock Up 8% - Tale of the Tape May 15 2015
AcelRX Takes Flight With New Department of Defense Contract May 14 2015
AcelRx Awarded Contract from Department of Defense to Advance ARX-04 May 14 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement May 14 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... May 08 2015
10-Q for AcelRx Pharmaceuticals, Inc. May 07 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 06 2015
10-K for AcelRx Pharmaceuticals, Inc. May 05 2015
The 52-Week Low Club for Tuesday May 05 2015
ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... May 05 2015
US STOCKS-Wall St lower as weak trade data offsets rally in oil prices May 05 2015
US STOCKS-Wall St set for lower open as trade data suggests GDP contraction May 05 2015
ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 05 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx... May 04 2015
AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial... May 04 2015
5 Key After-Hours Movers on Monday May 04 2015
FDA rejects AcelRx's request for meeting on pain drug device May 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK